BofA warns Fed risks policy mistake with early rate cuts
SAN DIEGO - DexCom , Inc. (NASDAQ:DXCM) reported second-quarter earnings and revenue that beat analyst expectations, but shares tumbled 4% as investors appeared unimpressed with the company’s performance despite raised guidance.
The continuous glucose monitoring (CGM) technology provider posted adjusted earnings of $0.48 per share for the second quarter, exceeding analyst estimates of $0.45. Revenue climbed 15% YoY to $1.16 billion, surpassing the consensus forecast of $1.12 billion.
DexCom’s U.S. revenue grew 15% to $841 million, while international revenue increased 16% to $316.1 million. The company’s sensor and other revenue, which represents 97% of total revenue, jumped 18% YoY to $1.12 billion, offsetting a 31% decline in hardware revenue.
"During the quarter, Dexcom delivered strong revenue results, presented compelling clinical data at ADA, and further advocated for expanded coverage in key growth markets," said Kevin Sayer, DexCom’s chairman and CEO.
Following the results, DexCom raised its full-year 2025 revenue guidance to $4.6-4.625 billion from its previous forecast, while maintaining its non-GAAP gross profit margin guidance of approximately 62% and operating margin of about 21%.
The company also announced a leadership transition, with Jake Leach set to become CEO effective January 1, 2026. Leach, who has been with DexCom for 21 years and currently serves as president and chief operating officer, will succeed Kevin Sayer, who will remain as executive chairman.
A significant milestone during the quarter was FDA clearance for the Dexcom G7 15 Day CGM System, which extends the wear time of the company’s continuous glucose monitoring sensors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.